Cancer Family
Melanocytic Neoplasm
CI-CAN-00000026Explore in graph →
Non-malignant609 active trials13 approved drugs233 evidence items
- NCIt
- C7058
Loading cancer entity…
Cancer Family
CI-CAN-00000026Explore in graph →
Clinical trials
3,258 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04223648 | Programmed Cell Death 1 + Selected Cell Therapy With Durvalumab (MEDI4736) and Tremelimumab in Metastatic Melanoma | withdrawn | Early Phase 1 | 0 | Yale UniversityOTHER | 0 | Nov 22, 2021 | clinicaltrials |
| NCT04285749 | Prevention of Recurrence and Metastasis in Genetically High-Risk Melanomas | withdrawn | Early Phase 1 | 0 | Case Comprehensive Cancer CenterOTHER | 0 | Jul 27, 2020 | clinicaltrials |
| NCT03022565 |
| Vorinostat in Patients With Class 2 High Risk Uveal Melanoma |
| withdrawn |
| Early Phase 1 |
| 0 |
| University of MiamiOTHER |
| 0 |
| Feb 6, 2020 |
| clinicaltrials |
Data updated 22 days agoSource updated Nov 22, 2021source: clinicaltrials